Q-omics provides the consensus-scored OR7E122P profile across patient tissues and cancer cell-line models. OR7E122P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR7E122P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, OR7E122P RNA expression shows 11,473 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BRCA, and THYM as cancer lineages where OR7E122P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E122P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E122P survival associations across molecular data types. OR7E122P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E122P RNA expression–survival associations across cancer types. High OR7E122P expression shows unfavorable associations in KIRC, MESO, LGG, ACC and BLCA, but favorable associations in UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OR7E122P RNA expression.
This table summarizes OR7E122P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E122P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E122P shows lower tumor expression in LUSC and COAD and higher tumor expression in BRCA, BLCA and CHOL. The BRCA box plot shows higher OR7E122P RNA expression in tumor versus normal tissue (log2 FC = +0.188, t-test p < 0.001).
This table shows molecular features associated with OR7E122P in patient tissues and cancer cell lines. In patient samples, OR7E122P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
